Shots:
- The EC has approved Adcetris (brentuximab vedotin) + ECADD (etoposide, cyclophosphamide, doxorubicin, dacarbazine & dexamethasone) to treat adults with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma following CHMP’s positive opinion in Apr 2025
- Approval was based on P-III (HD21) trial assessing Adcetris + ECADD vs escalated doses of BEACOPP in above pts, which met its co-1EPs with superior safety as per treatment-related morbidity & non-inferior PFS
- Adcetris is also being evaluated in P-III (ECHELON-1) trial for 1L Hodgkin lymphoma, P-III (ECHELON-2) trial for 1L CD30-positive peripheral T-cell lymphomas & additional trials in various CD30-positive malignancies
Ref: Businesswire | Image: Takeda| Press Release
Related News:- Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
